Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): A randomized controlled study

Journal of Bone and Mineral Research

Volumn 27, Issue 4, 2012, Pages 781-788

  Sikjaer, Tanja ^a   Rejnmark, Lars ^a   Thomsen, Jesper Skovhus ^b   Tietze, Anna ^a   Brüel, Annemarie ^b   Andersen, Gratien ^a   Mosekilde, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

bone densitometry; bone QCT; hypoparathyroidism; PTH PTHrP

Indexed keywords

CREATININE; OSTEOCALCIN; PLACEBO; RECOMBINANT PARATHYROID HORMONE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MARROW BIOPSY; BONE STRUCTURE; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HAVERSIAN CANAL; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPOPARATHYROIDISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; POROSITY; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE; TREATMENT OUTCOME;

ADULT; AGED; BONE DENSITY; FEMALE; HUMANS; HYPOPARATHYROIDISM; ILIUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; X-RAY MICROTOMOGRAPHY;

EID: 84858718686     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1493     Document Type: Article

References (50)

1. Shoback D,. Clinical practice. Hypoparathyroidism. N Engl J Med. 2008; 359: 391-403.
2. Poole KE, Reeve J,. Parathyroid hormone-a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005; 5: 612-7. (Pubitemid 41614461)
3. Kanzawa M, Sugimoto T, Kanatani M, Chihara K,. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol. 2000; 142: 661-4. (Pubitemid 30399499)
4. Mosekilde L,. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008; 69: 1-19. (Pubitemid 351863591)
5. Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L,. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000; 321: 598-602.
6. Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P,. Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 1996; 18: 103-8. (Pubitemid 26092589)
7. Seeman E, Wahner HW, Offord KP, Kumar R, Johnson WJ, Riggs BL,. Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest. 1982; 69: 1302-9. (Pubitemid 12081058)
8. Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC,. Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2003; 88: 3155-9. (Pubitemid 36877488)
9. Abugassa S, Nordenstrom J, Eriksson S, Sjoden G,. Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab. 1993; 76: 1617-21. (Pubitemid 23164388)
10. Compston JE,. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2007; 40: 1447-52. (Pubitemid 46756408)
11. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr., Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980; 280: 1340-4. (Pubitemid 10124272)
12. Jilka RL,. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40: 1434-46. (Pubitemid 46756429)
13. Datta NS, Abou-Samra AB,. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009; 21: 1245-54.
14. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148-58. (Pubitemid 40962421)
15. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J,. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19: 1842-4. (Pubitemid 41598769)
16. Frolik CA, Black EC, Cain RL, Satterwhite JH, Brown-Augsburger PL, Sato M, Hock JM,. Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure. Bone. 2003; 33: 372-9. (Pubitemid 37103254)
17. Mosekilde L, Torring O, Rejnmark L,. Emerging anabolic treatments in osteoporosis. Curr Drug Saf. 2011; 6: 62-74.
18. Thomas T,. Intermittent parathyroid hormone therapy to increase bone formation. Joint Bone Spine. 2006; 73: 262-9.
19. Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP,. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010; 21: 1927-34.
20. Winer KK, Yanovski JA, Cutler GB Jr., Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA. 1996; 276: 631-6. (Pubitemid 26278069)
21. Winer KK, Yanovski JA, Sarani B, Cutler GB Jr., A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998; 83: 3480-6. (Pubitemid 28500875)
22. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr., Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003; 88: 4214-20. (Pubitemid 37153722)
23. Winer KK, Sinaii N, Peterson D, Sainz B Jr, Cutler GB Jr., Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism. J Clin Endocrinol Metab. 2008; 93: 3389-95.
24. Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr., Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010; 95: 2680-8.
25. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L,. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011; 26: 2358-70.
26. Khoo BC, Brown K, Cann C, Zhu K, Henzell S, Low V, Gustafsson S, Price RI, Prince RL,. Comparison of QCT-derived and DXA-derived areal bone mineral density and T scores. Osteoporos Int. 2009; 20: 1539-45.
27. Thomsen JS, Laib A, Koller B, Prohaska S, Mosekilde L, Gowin W,. Stereological measures of trabecular bone structure: comparison of 3D micro computed tomography with 2D histological sections in human proximal tibial bone biopsies. J Microsc. 2005; 218: 171-9. (Pubitemid 40646647)
28. Jerome CP, Burr DB, Van BT, Hock JM, Brommage R,. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone. 2001; 28: 150-9. (Pubitemid 32140971)
29. Strandh J,. Microchemical studies on single Haversian systems. IV. Distribution of calcium, phosphorus and nitrogen in bone tissue from a case of osteopetrosis. Acta Soc Med Ups. 1962; 67: 232-8.
30. Sato K, Byers PD,. Quantitative study of tunneling and hook resorption in metabolic bone disease. Calcif Tissue Int. 1981; 33: 459-66. (Pubitemid 12181097)
31. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY,. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res. 2007; 22: 260-73. (Pubitemid 46167797)
32. Fox J, Newman MK, Turner CH, Guldberg RE, Varela A, Smith SY,. Effects of treatment with parathyroid hormone 1-84 on quantity and biomechanical properties of thoracic vertebral trabecular bone in ovariectomized rhesus monkeys. Calcif Tissue Int. 2008; 82: 212-20.
33. Miller MA, Bare SP, Recker RR, Smith SY, Fox J,. Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84. Bone. 2008; 42: 1175-83.
34. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB,. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res. 2009; 24: 597-605.
35. Heino TJ, Kurata K, Higaki H, Vaananen HK,. Evidence for the role of osteocytes in the initiation of targeted remodeling. Technol Health Care. 2009; 17: 49-56.
36. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC,. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007; 22: 1492-501. (Pubitemid 351229319)
37. Manolagas SC, Parfitt AM,. What old means to bone. Trends Endocrinol Metab. 2010; 21: 369-74.
38. Verborgt O, Gibson GJ, Schaffler MB,. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res. 2000; 15: 60-7. (Pubitemid 30026933)
39. Frost HM,. Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res. 1979; 143: 227-44. (Pubitemid 10186989)
40. Rowland RE, Marshall JH,. Radium in human bone: the dose in microscopic volumes of bone. Radiat Res. 1959; 11: 299-313.
41. Rubin MR, Dempster DW, Sliney J, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP,. PTH(1-84) administration reverses abnormal bone remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011; 26: 2727-36.
42. Malluche HH, Mawad HW, Monier-Faugere MC,. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011; 26: 1368-76.
43. Mosekilde L, Melsen F,. Morphometric and dynamic studies of bone changes in hypothyroidism. Acta Pathol Microbiol Scand A. 1978; 86: 56-62. (Pubitemid 8288568)
44. Nottestad SY, Baumel JJ, Kimmel DB, Recker RR, Heaney RP,. The proportion of trabecular bone in human vertebrae. J Bone Miner Res. 1987; 2: 221-9.
45. Eastell R, Mosekilde L, Hodgson SF, Riggs BL,. Proportion of human vertebral body bone that is cancellous. J Bone Miner Res. 1990; 5: 1237-41.
46. Rubin MR, Bilezikian JP,. Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq Bras Endocrinol Metabol. 2010; 54: 220-6.
47. Duan Y, De L V, Seeman E,. Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab. 1999; 84: 718-22. (Pubitemid 29075711)
48. Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ,. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008; 93: 2166-72. (Pubitemid 351831531)
49. Thomsen JS, Mosekilde LI, Gasser JA,. Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone. 1999; 25: 561-9. (Pubitemid 29469462)
50. Thomsen JS, Ebbesen EN, Mosekilde L,. Static histomorphometry of human iliac crest and vertebral trabecular bone: a comparative study. Bone. 2002; 30: 267-74. (Pubitemid 34044327)